Multiple endogenous receptors and matrix binding partners

"Multiple endogenous receptors and matrix binding partners" is a collective pharmacological designation used to describe the multifaceted interaction profile of certain therapeutic growth factors and cytokines. This term does not refer to a single protein but rather to a functional network comprising high-affinity transmembrane receptors (such as Platelet-Derived Growth Factor Receptors or Fibroblast Growth Factor Receptors) and various components of the extracellular matrix (ECM), including heparan sulfate proteoglycans and collagen (DrugBank DB00071; PubMed: 10692449). These interactions are essential for the regulation of cellular processes such as proliferation, migration, and differentiation, which are critical for tissue repair and development. In clinical practice, drugs targeting this complex system, such as Becaplermin for diabetic foot ulcers or Palifermin for oral mucositis, leverage the ECM's ability to stabilize ligands and present them to their respective receptors in a spatially controlled manner (StatPearls; PubMed: 15107442). However, the broad biological impact of stimulating these multiple pathways necessitates careful monitoring for adverse effects, including the potential for accelerated malignancy in patients with pre-existing cancers.

Other names

Endogenous receptors and ECM binding partnersGrowth factor-ECM complexesExtracellular matrix binding partners

The mechanism involves the binding of exogenous ligands to specific endogenous cell-surface receptors (e.g., PDGFR or FGFR), triggering intracellular signaling cascades, while simultaneously interacting with extracellular matrix (ECM) components that stabilize the ligand and modulate its local concentration (DrugBank DB00071; PubMed: 10692449).